Patents Assigned to Rosetta-Genomics
  • Patent number: 7777022
    Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: August 17, 2010
    Assignee: Rosetta Genomics, Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel
  • Patent number: 7759478
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: July 20, 2010
    Assignee: Rosetta Genomics Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7709616
    Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: May 4, 2010
    Assignee: Rosetta Genomics Inc.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7696342
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: April 13, 2010
    Assignee: Rosetta Genomics, Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7696334
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: April 13, 2010
    Assignee: Rosetta Genomics, Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7687616
    Abstract: The present invention describes a novel approach whereby small molecules may be used to modulate activity of microRNA and GAM oligonucleotides. This mode of therapy allows inter alia up regulation of a disease-related target gene of novel GAM oligonucleotides of the present invention, by countering the activity of a GAM oligonucleotides which naturally inhibits expression of that target gene. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 30, 2010
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel
  • Patent number: 7655785
    Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 15454 GAM precursors oligonucleotides, and 681 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: February 2, 2010
    Assignee: Rosetta Genomics Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7642348
    Abstract: Described herein are novel polynucleotides associated with prostate cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of prostate cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: January 5, 2010
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7618814
    Abstract: The present invention relates to a first group of novel genes, here identified as genomic address messenger or GAM genes, and a second group of novel operon-like genes, here identified as genomic record or GR genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 8607 GAM genes, and 1096 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: November 16, 2003
    Date of Patent: November 17, 2009
    Assignee: Rosetta Genomics Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7592441
    Abstract: Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: September 22, 2009
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Publication number: 20080318210
    Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 15484 GAM precursors oligonucleotides, and 699 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Application
    Filed: April 2, 2004
    Publication date: December 25, 2008
    Applicant: ROSETTA GENOMICS
    Inventor: Itzhak Bentwich
  • Publication number: 20080188428
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an operon-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Application
    Filed: October 30, 2003
    Publication date: August 7, 2008
    Applicant: Rosetta Genomics
    Inventor: Itzhak Bentwich
  • Patent number: 7250496
    Abstract: The present invention relates to a first group of novel genes, here identified as “genomic address messenger” or “GAM” genes, and a second group of novel operon-like genes, here identified as “genomic record” or “GR” genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 20600 GAM genes, and 6635 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: July 31, 2007
    Assignee: Rosetta Genomics Ltd.
    Inventor: Isaac Bentwich
  • Patent number: 7217807
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: May 15, 2007
    Assignee: Rosetta Genomics Ltd
    Inventor: Itzhak Bentwich
  • Publication number: 20070077553
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “Viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an “operon”-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Application
    Filed: October 30, 2003
    Publication date: April 5, 2007
    Applicant: ROSETTA GENOMICS
    Inventor: Itzhak Bentwich
  • Publication number: 20070042380
    Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Application
    Filed: May 14, 2004
    Publication date: February 22, 2007
    Applicant: ROSETTA GENOMICS
    Inventors: Itzhak Bentwich, Amir Avniel
  • Publication number: 20070042381
    Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Application
    Filed: May 26, 2004
    Publication date: February 22, 2007
    Applicant: Rosetta Genomics
    Inventors: Itzhak Bentwich, Amir Avniel
  • Publication number: 20070042982
    Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Application
    Filed: April 2, 2004
    Publication date: February 22, 2007
    Applicant: ROSETTA GENOMICS
    Inventor: Itzhak Bentwich
  • Publication number: 20070031843
    Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various bacterial infections. Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Application
    Filed: May 24, 2004
    Publication date: February 8, 2007
    Applicant: ROSETTA GENOMICS
    Inventors: Itzhak Bentwich, Amir Avniel
  • Publication number: 20070031823
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Application
    Filed: August 28, 2003
    Publication date: February 8, 2007
    Applicant: ROSETTA GENOMICS
    Inventor: Itzhak Bentwich